Aggredyne Increases IP Portfolio to Four Patents
Company begins international distribution of its AggreGuide^TM A-100 platelet
HOUSTON -- January 15, 2013
Aggredyne, Inc., a Houston-based biomedical diagnostics company that is
defining a new standard for platelet function, has added a fourth patent to
its intellectual property portfolio. The new patent, "Systems for Measuring
Properties of a Physiologic Fluid Suspension," provides the foundation to
expand the AggreGuide^TM platform to other coagulation tests, including
heparin, Coumadin® (warfarin) and collagen.
"Aggredyne developed its system to be expandable, and this patent allows us to
move beyond platelets into the full arena of coagulation testing," said
Chairman & CEO Edward R. Teitel, MD, JD. "For the patient, it will mean only
one tube of blood; for the clinic, one countertop instrument instead of two or
more. For our shareholders, it means Aggredyne can broaden beyond a single
product and expand testing in areas related to the effectiveness of
About Aggredyne’s new distributor network
With its CE Mark in place, Aggredyne is identifying high-quality international
distributors to roll out its platelet function analyzers worldwide. The
company recently signed an exclusive distribution agreement with NODIA for the
Benelux (Belgium, The Netherlands and Luxembourg). It also signed or is
completing distributor agreements in Turkey, Egypt, Israel, Greece/Cyprus,
India and Scandinavia and is negotiating with distributors in several other
“In building a strong distributor network, we are focusing initially on areas
that can use our inexpensive, single-channel AggreGuide A-100, but will be
expandable to our fully automated, multi-test instrument, the A-600,” reported
Todd Kronshage, executive vice president of sales and marketing.
ABOUT AGGREDYNE, INC.
Aggredyne, Inc. (www.aggredyne.com) is a biomedical company founded in 2011 to
commercialize the AggreGuide^TM platelet function analyzer. The AggreGuide
system is an in-vitro diagnostic test that measures how sticky a patient’s
platelets are and how well the patient is responding to antiplatelet
medications such as aspirin, Plavix® (clopidogrel), Effient® (prasugrel) and
Registered trademarks: Coumadin (Bristol-Myers Squibb), Plavix (Sanofi),
Effient (Eli Lilly and Company), Brilinta (AstraZeneca group of companies).
SAFE HARBOR STATEMENT
This release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Statements regarding Aggredyne’s
business that are not historical facts are “forward-looking statements,” which
involve risks and uncertainties that could cause actual results to differ
materially from any future results, performance, or achievements expressed or
implied by such statements.
Edward R. Teitel, MD, JD, 713.636.5996 (office)
Public Relations Counsel
Sally I Evans, APR, 713.660.7990 (office)
Press spacebar to pause and continue. Press esc to stop.